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ABSTRACT 
Niemann Pick type C disease (NPC) is a rare lysosomal storage disorder characterized by a progressive 
accumulation of cholesterol in the late endosomal/lysosomes compartment leading to cellular dysfunction and 
organ failure. Symptoms include ataxia, dysarthria, cognitive dysfunction, and seizures. Although average life 
expectancy is below 20, there are no FDA approved treatment available making it a serious unmet medical 
need. Clinical trials with 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) has shown promise in cholesterol 
normalization within NPC cells.  However, HP-beta-CD treatment has been shown to cause ototoxicity in NPC 
patients at high dosages. Supramolecular complexes known as polyrotaxanes have been synthesized in hopes 
of decreasing the amount of free HP-beta-CD in the body that will lead to hearing loss. The solubility of 
rotaxanes threaded with only HP-beta-CD in aqueous systems is low, but has seen an increase with the addition 
of sulfobutyl-beta-cyclodextrin (SBE-beta-CD). In this study, polyrotaxanes with varying amounts of HP-beta-CD 
and SBE-beta-CD were synthesized and used to treat NPC1 fibroblasts. Filipin staining and fluorescent imaging 
were performed on these fibroblasts to assess the levels of cholesterol after treatment thus finding the optimum 
ratio of HP-beta-CD to SBE-beta-CD. 
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